Cardiovascular disease (CVD) is the leading cause of death among patients with end-stage kidney disease (ESKD) who are undergoing hemodialysis, yet many standard cardioprotective therapies have not been effective in reducing CVD in this patient population.1 This reality has motivated the quest to identify dialysis-related and kidney disease–specific factors that promote CVD.
Hall RK, Scialla JJ. Vitamin D Receptor Agonists for Patients Undergoing Hemodialysis. JAMA. 2018;320(22):2319–2321. doi:10.1001/jama.2018.17477
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: